Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
Sign Up to like & getrecommendations! Published in 2018 at "Oncology reports"
DOI: 10.3892/or.2018.6248
Abstract: Despite debulking surgery and good initial response to chemotherapy, the majority of patients with advanced ovarian cancer relapse and succumb to their disease. Thus, there is a pressing need to improve treatment outcome. In the… read more here.
Keywords: synergistic antitumor; antitumor effects; scriptaid bortezomib; ovarian cancer ... See more keywords